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The potency of a series of opioid and non-opioid psychotomimetic drugs to inhibit the specific binding of 
[3H]PCP and (+)-[3H]SKF-10,047 to rat cerebral cortical membranes was examined. (+)-PCMP, the 
3-methylpiperidino analog of PCP, was a potent inhibitor of the specific binding of both ligands. All of 
the other 12 compounds examined, however, displayed a 3-277-fold selectivity for either [3H]PCP or 
( +)-[3H]SKF-10,047 binding. These results suggest hat although these opioid and non-opioid psychotomi- 
metics bind to both sites, most have significantly different affinities. The binding sites for [3H]PCP appear 
to be distinct from the ‘sigma’ binding sites labeled with (+)-[3H]SKF-10,047. 
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1. INTRODUCTION 
Psychotomimetic behavior may be induced in 
man by many drugs including phencyclidine (PCP) 
and the benzomorphans N-allylnormetazocine 
(SKF-10,047), cyclazocine and pentazocine. At- 
tempts to delineate the neurochemical mechanism 
of action of psychotomimetic drugs has focused on 
their interactions with specific central nervous 
system (CNS) receptors. Using the chronic spinal 
dog preparation, racemic SKF-10,047 was the pro- 
totypic agonist for identifying the sigma opioid 
receptor [l]. PCP has been shown to produce 
similar pharmacological actions to SKF-10,047 
when tested in this preparation [2]. More recently, 
receptor binding studies using radiolabeled 
psychotomimetic drugs have been employed to in- 
vestigate their site(s) of action. Using these pro- 
cedures, specific CNS binding sites for [3H]PCP 
and ( +)-[3H]SKF-10,047 have been demonstrated 
[3-81. Although it is not clear if the (+)- 
[3H]SKF-10,047 binding site is structurally related 
to the classical sigma opioid receptor, the question 
remains as to whether the psychotomimetic ben- 
Phencyclidine receptor Psychotomimetic activity 
zomorphans bind to the same site in the CNS as the 
PCP-like compounds. Behavioral evidence and 
some receptor binding studies suggest that these 
sites are identical [3-5,9-111, however, other 
receptor binding and neurochemical studies suga 
gest that these sites are distinct [6,7,12,13]. To ad- 
dress this issue, we compared the relative potencies 
of several benzomorphans, PCP analogs and 
butaclamol enantiomers for inhibiting the binding 
of (+)-[3H]SKF-10,047 and [3H]PCP to rat 
cerebral cortical membranes. ( - )-Butaclamol has 
been shown to inhibit potently the binding of ( + )- 
[3H]SKF-10,047, however, its effects on the 
[3H]PCP site have not been reported [7]. With the 
exception of ( +)-PCMP which showed similar 
potencies for both sites, all of the other com- 
pounds were more potent inhibitors of binding of 
either ( +)-[3H]SKF-10,047 or [3H]PCP. Thus, 
although some PCP derivatives are capable of 
binding to the ‘sigma’ receptor (as defined by ( + )- 
[3H]SKF-10,047) at low concentrations (and vice 
versa) these 2 recognition sites appear to be phar- 
macologically distinct. 
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2. MATERIALS AND METHODS 
Cerebral cortices from adult male Sprague- 
Dawley rats (150-200 g) were dissected on ice, 
pooled and homogenized in 25 vols (w/v) of 
50 mM Tris-HCl buffer (pH 7.7 at 22°C) using a 
Polytron (Brinkmann, Westbury, NY, PT 10 
probe, 15 s). The homogenate was centrifuged at 
37000 x g and the pellet resuspended in the 
original volume of Tris buffer. This procedure was 
repeated twice and the final pellet resuspended in 
8 vols of 50 mM Tris-HCl buffer (pH 7.7, 22°C). 
loo-p1 aliquots of tissue (approx. 1 mg protein) 
were added to 0.9 ml distilled/deionized water (i.e. 
final Tris concentration = 5 mM) containing (+)- 
[3H]SKF-10,047 (2 nM, spec. act. 43.3 Ci/mmol, 
NEN, Boston, MA) or [3H]PCP (4 nM, spec. act. 
49.9 Ci/mmol, NEN) in the presence or absence of 
drugs. Non-radioactive SKF-10,047 (10 PM) or 
PCP (10 PM) was used to define non-specific 
binding in the respective binding assay. Incuba- 
tions for the (+)-[3H]SKF-10,047 or [3H]PCP 
assays were carried out at 22°C for 45 min or 4°C 
for 60 min, respectively (cf. [4,6]). At the comple- 
tion of the incubation, the assay was terminated by 
rapid filtration using a cell harvester (Brandel, 
Gaithersburg, MD) over Whatman GF/B or GF/C 
filters that were presoaked in 0.5% polyethylene- 
imine to reduce nonspecific filter binding of radio- 
ligand. The filters were washed 3 times with 4 ml 
ice-cold 5 mM Tris-HCl buffer (pH 7.7). Under 
these conditions, there was no significant displace- 
ment of the radioactive ligands from the filters by 
non-radioactive drugs. The filters were placed in 
10 ml Readi-Solv MP (Beckman) and the radioac- 
tivity quantified by conventional liquid scintilla- 
tion spectroscopy. Specific binding, defined as the 
difference between total and nonspecific binding, 
was approx. 77% for [3H]PCP and 50% for (+)- 
[3H]SKF-10,047. 
SKF-10,047, PCP, N-[ 1-(2-thienyl)cyclo- 
hexyllpiperidine (TCP) and N-ethyl-l-phenylcyclo- 
hexylamine (PCE) were supplied by Dr Richard 
Hawks (NIDA). The following compounds were 
synthesized at NIH: 1-( 1 -phenylcyclohexyl)-3- 
methylpiperidine (PCMP) and 4-fluoro- 1-[ l-(2- 
thienyl)cyclohexyl]piperidine (F-TCP). Dexoxa- 
drol and levoxadrol were generously supplied by 
the Upjohn Co. (Kalamazoo, MI) and pentazocine 
and ( + )-cyclazocine by Sterling Winthrop (Rens- 
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selaer, NY). The enantiomers of butaclamol were 
purchased from Research Biochemicals (Wayland, 
MA). 
3. RESULTS 
The ( +) enantiomer of PCMP was a potent in- 
hibitor of specific [3H]PCP and (+)- 
[3H]SKF-10,047 binding to rat cerebral cortical 
membranes (fig. 1 A, table 1). The I& values were 
30 * 5 nM (mean f SE) and 30 + 6 nM for 
[3H]PCP and ( +)-[3H]SKF-10,047, respectively 
(fig.lA, table 1). (+ )-PCMP was 6.7-fold more 
potent than ( - )-PCMP at inhibiting (+)- 
[3H]SKF-10,047 binding and 51.7-fold more po- 
tent than (-)-PCMP at inhibiting [3H]PCP 
binding (fig. 1, table 1). There was a significant dif- 
ference between the potency of (-)-PCMP in in- 
hibiting ( +)-[3H]SKF-10,047 vs [3H]PCP binding 
@ < 0.01). 
Dexoxadrol and the PCP analogs TCP, F-TCP 
and PCE were potent inhibitors of [3H]PCP 
binding but were only weak inhibitors of (+)- 
[3H]SKF-10,047 binding (table 1). Levoxadrol, the 
(+)PCMP HPCMP 
Fig.1. Inhibition of specific (+)-[‘H]SKF-10,047 and 
[3H]PCP binding by PCMP enantiomers. Rat cerebral 
cortical membranes were incubated in 5 mM Tris buffer 
with ( +)-[3H]SKF-10,047 (o-----o ) or [3H]PCP (C--O) 
in the presence or absence of the indicated 
concentrations of (+)-PCMP (A) or (-)-PCMP (B). 
Data represent the mean ? SE of 3 separate experiments 
each carried out in duplicate or triplicate. 
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Table 1 
Relative potencies of PCP and benzomorphan 
and butaclamol enantiomers for inhibiting 
[‘HJPCP and ( +)-[3H]SKF-10,047 binding 




clarify the relationship between these two binding 
sites. (+)-PCMP, the 3-methylpiperidino analog 
of PCP, was a potent inhibitor of the specific 
binding of both ligands to rat cerebral cortical 
membranes. The inhibition of binding of both 
radioligands was stereoselective since ( - )-PCMP 
was significantly less potent than ( + )-PCMP. ( - )- 
PCMP was more potent as an inhibitor of ( +)- 
[3H]SKF-10,047 binding than [3H]PCP binding. 
The effects of PCMP enantiomers on ( +)- 
[3H]SKF-10,047 binding have not been previously 
reported and suggests further that specific (+)- 
[3H]SKF-10,047 binding is stereoselectively in- 
hibited although the degree of stereoselectivity for 
(+)-[3H]SKF-10,047 is less than for [3H]PCP 
binding. The effects of the PCMP enantiomers on 
[3H]PCP binding is similar to that previously 
reported by our laboratory [ 14,151. 
October 1985 
Drug IGO WI) 
[3H]PCP ( +)-[3H]SKF-10,047 
PCP 40* 10 267 f 33 
( + )-PCMP 3Ok 5 3Ok 6 
( - )-PCMP 1830 f 600 200 f 29 
TCP 11+ 1 2300 + 700 
F-TCP 25* 5 2200 f 1400 
PCE 382 6 1300 f 300 
Dexoxadrol 33* 2 650 f 230 
Levoxadrol 17OOtI f 1600 5300 f 2300 
(+)-SKF-10,047 217 + 17 13* 3 
Pentazocine 3600 f 700 13* 1 
( + )-Cyclazocine 163 + 36 35* 2 
( - )-Butaclamol > 10000 48+ 21 
( + )-Butaclamol > 10000 4000 * 1000 
Values represent the mean f SE of the I& values 
(concentration inhibiting 50% of specific binding) of 3 
separate experiments 
(-) enantiomer of dexoxadrol, was a weak in- 
hibitor of both ligands. Pentazocine and ( +)- 
cyclazocine, analogs of SKF-10,047, were more 
potent inhibitors of ( +)-[3H]SKF-10,047 binding 
than [3H]PCP binding. (-)-Butaclamol was 
83-fold more potent than ( + )-butaclamol as an in- 
hibitor of ( +)-[3H]SKF-10,047 binding, however 
neither enantiomer of butaclamol at concentra- 
tions up to 10 PM inhibited [3H]PCP binding. The 
logarithmic correlation coefficient (Pearson’s 
product moment) between the ICSO values of these 
drugs in inhibiting ( +)-[3H]SKF-10,047 and 
[3H]PCP binding was 0.04 demonstrating that 
there is no significant correlation between the 
potencies of the drugs listed in table 1 to inhibit the 
binding of each ligand. 
4. DISCUSSION 
This study represents a systematic investigation 
of the inhibition of both ( +)-[3H]SKF-10,047 and 
[3H]PCP binding by butaclamol enantiomers, ben- 
zomorphans and PCP derivatives. The compounds 
used here were specifically chosen in an attempt o 
In this study, there were relatively large dif- 
ferences in the potencies of most drugs to inhibit 
[3H]PCP and ( +)-[3H]SKF-10,047 binding. The 
PCP analogs TCP, F-TCP, PCE and dexoxadrol 
were more potent inhibitors of [3H]PCP binding 
than ( +)-[3H]SKF-10,047 binding. Conversely, the 
butaclamol enantiomers and benzomorphans, pen- 
tazocine and (+ )-cyclazocine, were more potent 
inhibitors of the binding of ( +)-[3H]SKF-10,047 
than [3H]PCP. The effects of the fluoro derivative 
of TCP (F-TCP) on [3H]PCP or ( +)- 
[3H]SKF-10,047 binding have not been reported 
previously. The results of benzomorphans and 
butaclamol enantiomers on ( +)-[3H]SKF-10,047 
binding and PCP derivatives on [3H]PCP binding 
in terms of relative order of potencies are in agree- 
ment with previous studies [3,6,8,15]. The effects 
of butaclamol enantiomers on [3H]PCP binding 
have not been reported previously. In a recent 
report, Mendelsohn and co-workers [9] found a 
significant correlation between the 2 binding sites 
using certain benzomorphans and PCP analogs. 
We also found a significant correlation when 
similar drugs were used. However, extension of the 
work to include other compounds reduced the cor- 
relation coefficient to a statistically insignificant 
value. Our results, therefore, suggest that (+)- 
[3H]SKF-10,047 and [3H]PCP binding sites are 
distinct and support the hypotheses of Tam [6], 
Martin et al. [8] and Tam and Cook [7]. It is not 
clear from the present study, however, whether 
(+)-PCMP binds to a site common to [3H]PCP 
335 
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and ( +)-[3H]SKF-10,047 or if this compocnd coin- 
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